We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+21.5%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.75B
AUM Growth
+$332M
Cap. Flow
-$28.9M
Cap. Flow %
-0.5%
Top 10 Hldgs %
51.71%
Holding
444
New
223
Increased
65
Reduced
45
Closed
77

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$54.6M
2
KYTX icon
Kyverna Therapeutics
KYTX
+$40.8M
3
SGRY icon
Surgery Partners
SGRY
+$33.8M
4
LRMR icon
Larimar Therapeutics
LRMR
+$33.4M
5
ALHC icon
Alignment Healthcare
ALHC
+$30.6M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$62.6M
2
SWTX
SpringWorks Therapeutics
SWTX
+$60.2M
3
BAX icon
Baxter International
BAX
+$55M
4
VKTX icon
Viking Therapeutics
VKTX
+$36.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$28.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Industrials 0.71%
3 Technology 0.31%
4 Consumer Discretionary 0.26%
5 Financials 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$1.5B 26.12%
19,991,024
– –
VTRS icon
2
Viatris
VTRS
$20.1B
$255M 4.44%
21,395,052
+1,531,568
+8% +$18.4M
CNC icon
3
Centene
CNC
$32.8B
$187M 3.25%
2,381,044
+389,245
+20% +$30.1M
LRMR icon
4
Larimar Therapeutics
LRMR
$384M
$161M 2.8%
21,231,974
+4,290,617
+25% +$33.4M
AHCO icon
5
AdaptHealth
AHCO
$1.49B
$153M 2.65%
13,257,940
-350,000
-3% -$2.97M
CPRX
6
DELISTED
Catalyst Pharmaceutical
CPRX
$146M 2.53%
9,130,817
+241,916
+3% +$3.65M
OSCR icon
7
Oscar Health
OSCR
$8.77B
$139M 2.42%
9,373,097
-1,873,723
-17% -$25.7M
FUSN
8
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$136M 2.37%
6,401,000
– –
ACH
9
Accendra Health
ACH
$266M
$135M 2.35%
4,877,588
-352,191
-7% -$7.82M
MRUS
10
DELISTED
Merus
MRUS
$119M 2.08%
2,649,401
-370,500
-12% -$15M
KURA icon
11
Kura Oncology
KURA
$964M
$115M 2.01%
5,411,571
+98,838
+2% +$1.92M
IDYA icon
12
IDEAYA Biosciences
IDYA
$3.47B
$115M 2.01%
2,630,292
– –
SPRY icon
13
ARS Pharmaceuticals
SPRY
$695M
$113M 1.97%
11,077,927
– –
BKD icon
14
Brookdale Senior Living
BKD
$3.58B
$103M 1.8%
15,612,264
+819,000
+6% +$4.78M
RVMD icon
15
Revolution Medicines
RVMD
$39.6B
$99.6M 1.73%
3,090,073
– –
NBIX icon
16
Neurocrine Biosciences
NBIX
$17.2B
$95.3M 1.66%
691,004
-205,715
-23% -$28.1M
SGRY icon
17
Surgery Partners
SGRY
$2.09B
$95.1M 1.65%
3,186,803
+1,081,294
+51% +$33.8M
DCPH
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$80.7M 1.4%
5,127,270
-660,754
-11% -$10.2M
HLVX
19
DELISTED
HilleVax
HLVX
$66.6M 1.16%
4,004,231
– –
SWTX
20
DELISTED
SpringWorks Therapeutics
SWTX
$63.2M 1.1%
1,283,176
-1,301,200
-50% -$60.2M
EHAB
21
DELISTED
Enhabit
EHAB
$58.2M 1.01%
4,997,746
– –
NKTX icon
22
Nkarta
NKTX
$186M
$56.1M 0.98%
5,194,087
+1,794,087
+53% +$18.7M
BIO icon
23
Bio-Rad Laboratories Class A
BIO
$8.15B
$52.7M 0.92%
152,378
+803
+0.5% +$264K
BNTX icon
24
BioNTech
BNTX
$23.1B
$52.5M 0.91%
+569,574
New +$54.6M
EWTX icon
25
Edgewise Therapeutics
EWTX
$4.28B
$52.4M 0.91%
2,874,586
-1,058,551
-27% -$16.8M
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2024 Portfolio in Review

As of Q1 2024, Deerfield Management held 444 positions worth $5.75B, up 6.1% from $5.42B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q1 2024 filing shows 223 new, 65 increased, 45 reduced and 77 closed positions. Its largest new stake was BioNTech: 569,574 shares worth $52.5M. The largest sale was RayzeBio, Inc. Common Stock, an estimated $62.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 78% a quarter earlier, followed by Industrials and Technology.

  • Deerfield Management's largest Q1 2024 buy was BioNTech: 569,574 shares worth $52.5M.
  • Deerfield Management added most to Surgery Partners in Q1 2024, an estimated $33.8M increase.
  • Deerfield Management's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $60.2M.
  • Deerfield Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $62.6M.
  • Deerfield Management's ten largest holdings make up 52% of its $5.75B portfolio in Q1 2024.
  • Deerfield Management opened 223 new positions and closed 77 in Q1 2024.
  • Deerfield Management's portfolio value rose 6.1% quarter-over-quarter to $5.75B.

Based on Deerfield Management's 13F filing for Q1 2024, filed 15 May 2024.